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 Branched oligonucleotides with symmetric arms 6-15 which may contain biotin as 
a second recognition code were prepared. These molecules are designed to be 
used for the directed assembly of nanomaterials. The branched structure of the 
desired oligonucleotides was confirmed by mass spectrometry on small branched 
oliognucleotides, by gel electrophoresis and by hybridization with complementary 
oligonucleotide-nanoparticle conjugates followed by visualization of the 
complexes by transmission electron microscopy. 
 
Introduction.- Interest in branched nucleic acids has grown recently. Most of the 
work in this area was first focused on the study of branched oligoribonucleotides 
as splicing intermediates of eukaryotic mRNAs. [1, 2]. Later, the complexity of 
the synthesis of the branching molecules and the low yields triggered the search 
for non-nucleoside branching molecules such as derivatives of 1,3-
diaminopropanol [3] and pentaerythriol [4]. These branching molecules can be 
used to produce oligonucleotides carrying multiple labels to increase sensitivity in 
hybridization experiments [3, 4]. Moreover, oligonucleotides with three arms are 
suitable building blocks for template-directed synthesis of nanostructures [5, 6].  
Among the biological molecules, oligonucleotides have been used as 
template to assemble inorganic nanocrystals. The hybridization properties of the 
oligonucleotides permit assembly of gold nanoparticles at distances determined by 
the length of the oligonucleotides and also the formation of three-dimensional 
networks [7-10]. In addition, DNA can be metallized to form conducting wires 
between electrodes [11]. Single-walled carbon nanotubes have also been 
functionalized with DNA derivatives [12].  
We describe the preparation of branched oligonucleotides (scheme 1) 
consisting of two or more sequences connected by a non-DNA material such as 
hexaethyleneglycol. This type of oligonucleotide may be used to assemble 
nanomaterials. Moreover, the presence of biotin in these oligonucleotides may 
direct a nanoparticle to the middle of the structure using streptavidine carrying a 
nanoparticle [13, 14]. Here we describe the preparation of branched 
oligonucleotides with two, three and four arms of identical sequence. These 
molecules may allow the assembly of complex nanostructures by hybridisation of 
a few simple elements [15].  
 
 
Results. - 1. Synthesis of branched oligonucleotides carrying two identical arms. 
Oligonucleotides 6 and 7, with two identical arms, were prepared by sequential 
addition of phosphoramidites (scheme 2). Starting from the 3’-end, the first half of 
the sequence was assembled using standard phosphoramidites. Subsequently, 
hexaethyleneglycol (oligonucleotides 6 and 7) and biotin-tetraethyleneglycol 
(oligonucleotide 7) phosphoramidites were added. Finally, the second half of the 
molecule was assembled using reversed phosphoramidites.  
Next, the synthesis of oligonucleotides 8 and 9 which have the opposite 
polarity to oligonucleotides 6 and 7 was undertaken. In this case, synthesis was 
begun in the middle of the molecule using a solid support containing a branching 
molecule, and both strands were synthesized simultaneously (scheme 3). Although 
this strategy required a special solid support, there was no need for reversed 
phosphoramidites.  
1, 3-Diamino-2-propanol was reacted with γ-butyrolactone to yield the 
desired triol 1 (scheme 4) [3]. The two primary alcohols were protected with the 
(MeO)2Tr group by reaction of triol 1 with an excess of dimethoxytrityl chloride 
in pyridine [3]. Compound 2 was incorporated on controlled pore glass (CPG) 
using the hemisuccinate derivative (3) as described [16, 17].  
The resulting support carrying the symmetric branching molecule (4) was 
tested by the preparation of a short oligonucleotide sequence (8). After the 
assembly of four thymidines, the solid support was treated with ammonia and the 
resulting oligonucleotide 8 carrying two dimethoxytrityl [(MeO)2Tr] groups was 
purified by HPLC. One single peak (purity 97%) was obtained, which had the 
expected molecular weight (M+H found 3333, expected for C133H162N18O65P8 
3300).  
Branched oligonucleotide 9 which has two identical arms of 20 bases was 
prepared. The standard 1-µmol synthesis cycle was used. Overall synthesis yield, 
judged by the absorbance of the (MeO)2Tr group released on each detritylation, 
was 60% (98% step yield). In agreement with trityl values, analysis of the bis-
[(MeO)2Tr]-oligonucleotide 9 by HPLC gave a major peak in the area of elution 
of tritylated oligonucleotides which was 54% of the total absorbance. The sample 
that produced this peak was treated with acetic acid and analyzed by 15% 
polyacrylamide, 8M urea gel electrophoresis.  A single band with the mobility of a 
40-base oligonucleotide was observed (data not shown). 
 
2. Synthesis of branched oligonucleotides carrying three identical arms. The use 
of the symmetric branching molecule to prepare oligonucleotides carrying three 
branches was examined on oligonucleotides 10, 11 and 12. First, a short 
oligonucleotide (10) was prepared. Four thymidines were assembled using 
standard phosphoramidites.  Thereafter, the symmetric branching phosphoramidite 
(5) was added to the sequence and, finally, four more thymidines were assembled 
using standard phosphoramidites and coupling times of 5 min. After ammonia 
treatment, the desired oligonucleotide 10 was obtained and characterized by mass 
spectrometry (M+H found 3936, expected for C133H180N26O89P12 3938). 
Subsequently, the synthesis of oligonucleotides 11 and 12 was undertaken. The 
method was similar to the synthesis of oligonucleotides 8 and 9 (scheme 3). First 
the 20 mer sequence was built in the 3´->5’ direction using standard 
phosphoramidites and the hexaethyleneglycol phosphoramidite. In 
oligonucleotide sequence 12 the biotin-tetraethyleneglycol was added at this 
point. Thereafter, the symmetric branching phosphoramidite (5) was added to the 
sequence and, finally, the rest of the desired sequence was assembled in the 5’->3’ 
direction using reversed phosphoramidites and the hexaethyleneglycol 
phosphoramidite. During the assembly of the second part, we observed the 
duplication of the amount of (MeO)2Tr released during detritylation. This is in 
agreement with the duplication of the second part of the sequence. Coupling 
yields for the assembly of the second half were lower than the yields during the 
assembly of the first part (20% overall yield compared with 80%). This may be 
due to the use of reversed phosphoramidites and hexaethyleneglycol 
phosphoramidite and steric hindrance at the branching point. HPLC analysis 
revealed two products in the area of elution of (MeO)2Tr-containing 
oligonucleotides (Figure 1). We assigned the first peak to an oligonucleotide with 
two complete arms and a third one incomplete. This oligonucleotide contained a 
single (MeO)2Tr group, and so it eluted first. The second peak corresponds to the 
desired sequence carrying two (MeO)2Tr groups, and thus eluted later.  
A range of conditions were examined in an attempt to increase the yields 
of branched oligonucleotides. These changes include: a) increase the coupling 
time to 300 s, b) increase the amount of phosphoramidite by using 0.2 M solutions 
instead of 0.1 M solutions and c) a cycle with a double coupling protocol. All the 
changes improved the elongation of the second half of the oligonucleotide, the 
most effective being the increase of the coupling time and the double coupling 
protocol. The optimized cycle with increased coupling time and double coupling 
protocol was used for the preparation of oligonucleotides 11 and 12. Using the 
new cycle the overall yield rose from 20% to 80%, similar to the yields that were 
obtained without the introduction of the branching point. HPLC analysis gave two 
peaks in the area corresponding to (MeO)2Tr-containing oligonucleotides (Figure 
1). This time, the second peak, assigned to the desired sequences, was larger (area 
ratio in the second synthesis 2:3, area ratio in the first synthesis 3:1) than the first 
peak, assigned to truncated sequences. A similar result was obtained during the 
preparation of sequence 11. The products were analyzed by denaturing 
polyacrylamide gel electrophoresis (PAGE) (20% polyacrylamide, 8 M urea, 
Figure 2). As expected, the product with the desired length was in peak II. Peak I 
contained truncated sequences, mainly near the branching point (Figure 2). 
The trimeric structure of oligonucleotide 11 was confirmed by 
hybridization with complementary oligonucleotide carrying gold nanoparticles 
followed by visualization of the assemblies by transmission electron microscopy 
(TEM). Figure 3 shows groups of three particles obtained  by TEM of a sample 
resulting from hybridization of oligonucleotide 11 with its complementary 
sequence 16, carrying gold nanoparticles.    
 
3. Synthesis of branched oligonucleotides carrying four identical arms. The 
synthesis of oligonucleotides 13, 14 and 15 carrying four equal arms was 
undertaken. The synthetic strategy is shown in Scheme 5. The synthesis began at 
the middle of the molecule. The first branching point was generated with the solid 
support having the symmetric branching molecule (4) followed by the addition of 
the phosphoramidite of the symmetric branching molecule (5). In this way four 
hydroxyl groups were generated, on which the desired oligonucleotide sequence 
was assembled. First, a short oligonucleotide (13) was prepared. Four thymidines 
were assembled using standard phosphoramidites with increased coupling times. 
After ammonia treatment, the desired oligonucleotide 13 was obtained and 
characterized by mass spectrometry (M+H found 5832, expected for 
C197H276N38O131P18 5829). Afterwards, the synthesis of oligonucleotides 14 and 
15 was performed. A tetraethyleneglycol molecule was added between the 
branching points and the oligonucleotide sequences. The addition of 11 bases 
generated the 44mer oligonucleotide 13 and the addition of 20 bases generated the 
80mer oligonucleotide 14. For the assembly of the sequences, standard 
phosphoramidites were used on a 200-nmol synthesis cycle with increased 
coupling time. The assembly of the sequences was similar to standard synthesis, 
as judged by the absorbance of the (MeO)2Tr group (step coupling yield 98%). 
The resulting products were analyzed and purified by gel electrophoresis (10% 
polyacrylamide, 8M urea, Figure 4). Lanes 1, 2 and 5 contain synthetic linear 
oligonucleotides of 100, 100 and 33 bases. Lanes 3 and 4 contain the crude 
material from the synthesis of oligonucleotides 14 (44 bases) and 15 (80 bases). 
The 4-branched oligonucleotides ran faster than expected (especially 15). A broad 
band appeared on both oligonucleotides 14 and 15. The anomalous mobility is 
attributed to the structure of the branched oligonucleotide. The broad band is due 
to the isomers of the branching units.  
 Melting experiments performed with duplexes of oligonucleotides 14 and 
15 with their complementary oligonucleotides gave the same melting temperatures 
when compared with their linear analogues (Table 2). 
 
Discussion.  The ability to control the assembly of nanomaterials from well-
defined units is a key step that is expected to allow the exploitation of the 
technological potential of these materials. The use of the hybridisation properties 
of oligonucleotides is a promising approach [7-12]. In this paper branched 
oligonucleotides with identical arms which may carry biotin (scheme 1) were 
prepared. These oligonucleotides are designed to be used as templates for the 
controlled assembly of nanomaterials .  
 Two synthetic strategies were used for the preparation of two-armed 
oligonucleotides. The first approach consists of the sequential addition of the 
nucleoside and non-nucleoside units from one to the other end. The second 
approach consists of the parallel extension of the two arms from a central 
branching molecule. Both approaches gave good results but the second was the 
best solution for the synthesis of the 3’-3’ linked oligonucleotides such as 9 
because there is no need to use reversed phosphoramidites.  
 The preparation of three-armed oligonucleotides was performed by a 
combination of both methods. The first arm was prepared by sequential addition 
of monomers and the second and third arm were assembled in parallel. The 
coupling reaction was recalcitrant after the addition of the branching in the middle 
of the molecule. These difficulties were overcome by modifying the synthesis 
cycle by increasing coupling time and the concentration of monomers and by 
double coupling. Similar results were obtained during the synthesis of branched 
RNA [2] and these may be due to steric hindrance.  We showed that three-armed 
oligonucleotides can easily be purified from truncated sequences using reversed-
phase HPLC as developed for standard oligonucleotides.  
 Four-armed oligonucleotides were only obtained by the simultaneous 
assembly of the four strands. In addition to the results shown in this paper, we 
tried unsuccessfully to use asymmetric branching molecules and combine 
sequential and parallel additions (data not shown). Although the results obtained 
in the synthesis of three- and four-armed oligonucleotides are not directly 
comparable, we believe that parallel synthesis of more than one chain is more 
efficient near the solid support than in the middle of a DNA sequence (see also ref 
[5]).  
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Experimental Part 
 
General. Phosphoramidites and ancillary reagents used during oligonucleotide 
synthesis were from Applied Biosystems (PE Biosystems Hispania S.A., Spain), 
Cruachem (Cruachem Ltd., Scotland) and Glen Research (Glen Research Inc., 
USA). The rest of the chemicals were purchased from Aldrich, Sigma or Fluka 
(Sigma-Aldrich Química S.A., Spain). Long chain amino controlled pore glass 
(LCAA-CPG) was purchased from CPG (CPG, Inc., New Jersey, USA). Solvents 
were from S.D.S. (S.D.S., France). NAP-10 columns (Sephadex G-25) were 
purchased from Pharmacia Biotech. N,N’-Bis(4-hydroxybutyryl)-1,3-diamido-2-
propanol (1) and its bis[(MeO)2Tr]-protected derivative (2) were synthesized as 
described elsewhere [12]. Instrumentation. Oligonucleotide sequences were 
synthesized on a Applied Biosystems DNA synthesizer model 392 (Applied 
Biosystems, USA). Mass spectra (matrix-assisted laser desorption ionization time-
of-flight, MALDI-TOF) were provided by the Mass spectrometry service at the 
University of Barcelona. UV-Visible spectra were recorded on a Shimadzu UV-
2101PC and a HP8452A diode array spectrophotometer. Transmission electron 
microscopy was performed on a JEOL 2000 FX TEMSCAN.  
 
Preparation of solid-supports. Compound 2 [3] was reacted with succinic 
anhydride in the presence of N,N-dimethylaminopyridine in dichloromethane 
according to the literature [16]. Solid-support carrying the symmetric branching 
molecule was prepared by reacting the 3’-hemisuccinate derivative of the 
symmetric branching molecule (3) with amino controlled pore glass (long chain 
amino alkyl-CPG) using Ph3P and 2,2’-dithio-bis-(5-nitropyridine) [17] for 
condensation. Coupling time was increased from 5 min to 15 min obtaining a 
loading of 18 µmol·g-1. 
 Oligonucleotide Synthesis. Oligonucleotide sequences were prepared using 
standard (benzoyl- or isobutyryl-protected)  3’-[(2’-cyanoethyl)phosphoramidites] 
and reversed (benzoyl- or isobutyryl-protected)  5’-[(2’-
cyanoethyl)phosphoramidites]. Supports were obtained from commercial sources 
or prepared as described above. The symmetric branching phosphoramidite (5), 
the hexaethyleneglycol phosphoramidite and the biotin-tetraethyleneglycol 
phosphoramidite were from commercial sources (Cruachem, Scotland and Glen 
Research, USA). The tetraethyleneglycol phosphoramidite was prepared 
according to the literature [18]. 
 Oligonucleotides 6, 7, 10, 11 and 12 were prepared on 200-nmol scale 
using polystyrene supports (LV200, Applied Biosystems). The coupling time of 
the biotin and the hexaethyleneglycol phosphoramidites was increased from 30 to 
480 s. During the synthesis of the second half of oligonucleotides 11 and 12 yields 
were unsatisfactory. The following changes on the synthesis cycle were studied: 
a) increase of coupling time from 30 s to 300 s, b)  increase the phosphoramidite 
concentration using 0.2M soln. instead of 0.1M soln. of phosphoramidite and c) 
implementation a double coupling protocol. A new cycle with increased coupling 
time and double coupling protocol was used. The rest of the oligonucleotides were 
prepared on 1-µmol scale. Oligonucleotides 8 and 9 were prepared using the 
standard 1-µmol synthesis cycle. Oligonucleotides 13, 14 and 15 were prepared 
using a 200-nmol synthesis cycle with an increased coupling time (480 s).  
 Oligonucleotide carrying a thiol group at 5’end (16) was prepared on 1-
µmol scale using standard phosphoramidites, and the phosphoramidite of (MeO)2-
Tr-protected 6-hydroxyhexyl disulfide (Glen Research, USA).  
 Deprotection of oligonucleotides. The resulting supports were treated with 1ml of 
concentrated ammonia (overnight, 55ºC). Oligonucleotide support carrying a thiol 
group at the 5’-end was treated overnight with 1ml of 50 mM dithio-DL-threitol 
(DTT) in concentrated ammonia at 55ºC. The excess of DTT was eliminated with 
a Sephadex G-25 column (NAP-10, Pharmacia, Sweden) just prior to conjugation 
with gold nanoparticles.  
  
Purification of oligonucleotides. The products resulting from ammonia treatment 
were dissolved in water and purified by HPLC. Column : PRP-1, 10 µm 
(Hamilton, USA) (305 x 7mm), flow rate 3 ml/min. A 20min linear gradient from 
15 to 50% acetonitrile over 100mM aqueous triethylammonium acetate was used 
for oligonucleotides carrying the (MeO)2-Tr group. After removal of the (MeO)2-
Tr group with 80% acetic acid (30min) the resulting oligonucleotides were 
purified on the same column using a 20min linear gradient from 5 to 25% 
acetonitrile over 100 mM aqueous triethylammonium acetate. Oligonucleotides 14 
and 15 were first desalted with a Sephadex G-25 (NAP-10) column and, then, 
purified by gel electrophoresis.  
Yields after purification. 6 (3x200 nmols): 45 OD units.  7 (2x200 nmols): 26 OD 
units.  8 (1-µmol): 17 OD units. 9 (1-µmol): 8 OD units. 10, (200 nmols) 5 OD 
units. 11, (200 nmols) 7 OD units. 12, (2x 200 nmols) 19 OD units. 13, (200 
nmols) 5 OD units. 14 (200 nmols): 8 OD units after Sephadex before 
electrophoresis, 1.5 OD units after electrophoresis. 15 (200 nmols): 12 OD units 
after Sephadex before electrophoresis, 1 OD units after electrophoresis. 
 
Preparation of gold nanoparticles 
Gold nanoparticles with an average diameter of 5 nm were prepared by tannic 
reduction of a gold salt as described in detail in [19]. 3,3’,3’’-Phosphinidene-
tris(benzenesulfonic acid) trisodium salt (phosphine) was added to gold solution 
until final phosphine concentration of 0.5M. The mixture was stirred for 10 h. 
Solid NaCl was added to the solution until it turned from deep burgundy to purple 
color. The solution was centrifuged at 8,000 rpm for 20 min, the supernatant was 
discarded and the precipitated was redispersed in 0.5mM phosphine. Solution was 
precipitated again with NaCl, centrifuged and redispersed in 0.5× TBE buffer 
(final gold nanoparticle concentration 0.8µM).  
 
Preparation of oligonucleotide-gold conjugates.  
Thiolated oligonucleotide (16) complementary to oligonucleotides 11 and 15 was 
combined (50µM, 0.5× TBE buffer) with gold nanoparticle solution in 1:0.9 
Au:DNA molar ratio mixing well. The resulting solution was brought to 50mM 
NaCl (from 1M NaCl) and incubated overnight. 
Gold nanoparticles functionalized with thiol-DNA 16 were mixed with branched 
oligonucleotide 11 carrying 3 copies of complementary oligonucleotide in 
stoichiometric amounts. The resulting solutions 50mM in NaCl were incubated 
overnight prior to TEM characterization. 
 
Transmission Electron Microscopy. A Jeol 2000 FX TEMSCAN was used at an 
acceleration voltage of 80 keV to image the samples. A drop (10 µL) of the 
dispersion to be imaged was deposited for 1 min on carbon coated copper grid 
(400 mesh).  
Melting experiments. Melting experiments were performed by mixing equimolar 
amounts of two strands dissolved in a soln. that contained 0.15M NaCl, 0.05M 
Tris·HCl buffer (pH 7.5). Duplexes were annealed by slow cooling from 90 ˚C to 
room temperature. UV Absorption spectra and melting curves (absorbance vs 
temperature) were recorded in 1-cm path-length cells using a Shimadzu 
UV2101PC UV/VIS spectrophotometer (Shimadzu, Japan) with a temp. controller 
with a programmed temp. increase of 0.5˚/min. Melting curves were obtained 
monitoring the absorbance at 260 nm on duplex concentrations of approx. 2µM. 
Melting temperatures were measured at the maximum of the first derivative of the 
melting curve. Results: see Table 2. 
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 Table 1: Oligonucleotide sequences prepared 
 
Number Sequencea) 
6 3’-CGTAACTCGCTACGTCCGTC-heg-CTGCCTGCATCGCTCAATGC-3’ 
7 3’-CGTAACTCGCTACGTCCGTC-heg-bio-heg-CTGCCTGCATCGCTCAATGC-3’ 
8 5’-TTTT-bps-TTTT-5’ 
9 5’-CTGCCTGCATCGCTCAATGC-heg-bps-heg-CGTAACTCGCTACGTCCGTC-5’ 
10 3’-TTTT-bpp-(TTTT-5’)2 
11 3’-CGTAACTCGCTACGTCCGTC-heg-bpp-(-heg-CTGCCTGCATCGCTCAATGC-3’)2 
12 3’-CGTAACTCGCTACGTCCGTC-heg-bio-bpp-(-heg-CTGCCTGCATCGCTCAATGC-
3’)2 
13 (5’-TTTT)2-bpp-bps-bpp-(TTTT-5’)2 
14 (5’-TCTCCTCCTTC-heg)2-bpp-bps-bpp-(heg-CTTCCTCCTCT-5’)2 
15 (5’-CTGCCTGCATCGCTCAATGC-heg)2-bpp-bps-bpp-(heg-
CGTAACTCGCTACGTCCGTC-5’)2 
16 5’-thiol-hexyl-phosphate-AAAAAAGCATTGAGCGATGCAGGCAG-3’ 
a)heg: hexaethyleneglycol, bio: biotin-tetraethyleneglycol, bps: [-PO3-O(CH2)3-
CONH-CH2]2-CHOH, bpp: [-PO3-O(CH2)4-CONH-CH2]2-CHOPO3-  
 
Table 2: Melting temperatures of duplexes formed by oligonucleotides 14 and 15 
and the linear control sequences.  
 
Oligonucleotide Tm [ºC]a) 
14 45 
5’-TCTCCTCCTTC-3’ 46 
15 72 
5’-CTGCCTGCATCGCTCAATGC-3’ 72 
a) Complementary sequences: 3’-AGA GGA GGA AG-5’ and 3’-GAC GGA CGT 
AGC GAG TTA CG-5’, 0.050M Tris·HCl, 0.15M NaCl, pH 7.5, error in Tm is ±1 
º. 
 LEGENDS 
Scheme 1: Schematic representation of oligonucleotides described in this paper. 
 
Scheme 2. Outline of the synthesis of oligonucleotides 6 and 7 with two identical 
arms. 
 
Scheme 3. Outline of the synthesis of branched oligonucleotides 8, 9, 11 and 12 
with two and three identical arms. 
 
Scheme 4. Structure of the reagents used for the introduction of the symmetric 
branching molecule into oligonucleotides. 
  
Scheme 5. Outline of the synthesis of branched oligonucleotides 14 and 15 with 
four arms with identical sequence. 
 
Figure 1: HPLC profiles of (MeO)2Tr-containing oligonucleotides 11 (a) and 12 
(b) with three arms. Truncated sequences without (MeO)2Tr groups had a 
retention time of less than 5 minutes. Benzamide eluted at 7-8 minutes. Fraction I 
contained oligonucleotides with one single (MeO)2Tr group. Fraction II contained 
the desired sequence with two (MeO)2Tr groups.  
 
Figure 2: 20% Polyacrylamide, 8M urea gel electrophoresis of HPLC fractions I 
and II of oligonucleotides 11 and 12 with three arms. The gel was stained with 
STAINS-ALL. Lane 1: Fraction II, oligonucleotide 11. Lane 2: Fraction I, 
oligonucleotide 11. Lane 3: Fraction II, oligonucleotide 12. Lane 4: Fraction I, 
Oligonucleotide 12.  Lane 5: oligonucleotide 7. The double band of 
oligonucleotide 7 is due to the diastereoisomers of  biotin-tetraethyleneglycol 
molecule. 
 
Figure 3: Representative TEM images of trimeric DNA-gold nanoparticle 
assemblies. 
 
Figure 4: 10% Polyacrylamide, 8M urea gel electrophoresis of crude 
oligonucleotides 14 and 15 with four arms. The gel was stained with STAINS-
ALL. Lane 1 and lane 2 : synthetic oligonucleotides of 100 bases. Lane 3: 
branched oligonucleotide  15 (80 bases). Lane 4: branched oligonucleotide  14 (44 
bases). Lane 4: synthetic oligonucleotide of 34 bases. In these conditions the 
xylene cyanol (XC) dye ran as a 70-base oligonucleotide. 
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